MGEN - Miragen Therapeutics, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD

Miragen Therapeutics, Inc.

6200 Lookout Road
Boulder, CO 80301
United States
720-643-5200
http://www.miragen.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Dr. William Stuart Marshall Ph.D.Co-Founder, Pres, CEO & Director637kN/A1964
Dr. Paul D. RubinExec. VP of R&D508.4kN/A1954
Eric N. OlsonCo-Founder & Chairman of Scientific Advisory BoardN/AN/AN/A
Dr. Michael R. BristowCo-Founder & Member of the Scientific Advisory BoardN/AN/A1945
Dr. Marvin H. CaruthersScientific Advisory Board MemberN/AN/A1940
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. The company has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

Corporate Governance

Miragen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.